These anti-VEGF treatments include aflibercept, farcimab-svoa, bevacizumab, and the intravitreally-administered original version of ranibizumab (Lucentis). This new FDA approval for the implant is ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...